OCT 16, 2013 11:00 AM PDT

Embracing Complexity: Drosophila as a Tool to Develop Cancer Therapeutics

C.E. CREDITS: CE
Speakers
  • Associate Dean of the Graduate School of Biological Sciences and Professor of Oncological Sciences, Icahn School of Medicine at Mount Sinai
    Biography
      Dr. Cagan is a Professor in the Department of Developmental and Regenerative Biology and Associate Dean of the Graduate School of Biological Sciences of the Icahn School of Medicine at Mount Sinai. He is also Co-Founder of the biotechnology company Medros Inc. and Editor-in-Chief of Disease Models and Mechanisms. He is a world-renowned expert in the genetics of nervous system development and, more recently, Dr. Cagan has been a pioneer in using Drosophila for novel approaches to cancer and diabetes. Research in Dr. Cagans laboratory focuses on using the fruit fly Drosophila to develop complex models of diabetes and of breast, lung, colorectal, and thyroid cancers. Taking advantage of a century of powerful genetic tools, his laboratory has developed complex, multigenic disease models designed to model specific aspects of human disease. In addition to studying the mechanisms that direct cancer and diabetes, he has developed a novel robotics-based approach for screening whole animals for novel therapeutic drugs. This approach has helped identify the first chemotherapeutic for Medullary Thyroid Carcinoma, vandetanib. More recent work has used fly genetics to develop polypharmacological drugs and drug cocktails designed to address multiple pathways in a rational manner. His laboratory has also explored the links between diabetes and cancer, demonstrating how dietary sugar combines with specific oncogenes to render tumor insulin hypersensitive.

    Abstract:

    Cancer and diabetes are complex diseases that have proven difficult to treat in the clinics. Until recently, most efforts have focused on hitting individual therapeutic targets cleanly. Unfortunately, success rates in clinical trials have been low: in the case of cancer, success rates for individual drugs have commonly been in single digits. This suggests that our models are poorly predictive of useful therapeutics. One issue is disease complexity. Another is the importance of modeling disease in the context of the whole animal. I will discuss our efforts using Drosophila to build complex cancer and diabetes models in the context of the whole animal. We utilize genomic sequencing data to create multi-hit fly models, either of disease populations or of individual patients. We then use automated systems to screen libraries for useful drugs. In addition, I will describe how we combine Drosophila genetics plus medicinal chemistry to create new generation candidate therapeutics.


    Show Resources
    You May Also Like
    MAY 24, 2018 09:30 AM PDT
    C.E. CREDITS
    MAY 24, 2018 09:30 AM PDT
    DATE: May 24, 2018 TIME: 9:30PM PDT The current gold standard in in vitro pre-clinical cancer treatment screening remain cell lines,...
    MAY 03, 2018 11:00 AM PDT
    MAY 03, 2018 11:00 AM PDT
    DATE: May 3, 2018TIME: 11:00AM PDT, 2:00PM EDTWhile stress is one of the leading causes of neuropsychiatric disorders, the molecular underpinnings of how stress induces alterations in b...
    MAY 22, 2018 08:00 AM PDT
    C.E. CREDITS
    MAY 22, 2018 08:00 AM PDT
    DATE: May 22, 2018TIME: 08:00AM PDT The nuclear receptors pregnane X receptor (PXR) and constitutive androstane receptor (CAR) are closely related transcription factors that...
    APR 27, 2018 10:00 AM PDT
    C.E. CREDITS
    APR 27, 2018 10:00 AM PDT
    DATE: April 27, 2018TIME: 10:00am PST, 1:00pm ESTGlioblastoma (GBM) and Medulloblastoma (MB) are the most common adult and paediatric brain tumours, both of which can have devastating c...
    AUG 15, 2018 08:00 AM PDT
    C.E. CREDITS
    AUG 15, 2018 08:00 AM PDT
    DATE: August 15, 2018TIME: 08:00AM PDT, 11:00AM EDTThe failure of current chemotherapeutic strategies in the fight against cancer can be largely attributed to the occurrence of drug res...
    MAY 02, 2018 08:00 AM PDT
    C.E. CREDITS
    MAY 02, 2018 08:00 AM PDT
    Immunohistochemistry protocols, which utilize antibodies to visualize proteins in tissue sections, have many steps that need optimized to prevent non-specific background effects, artifacts, o...
    Loading Comments...